Sugi Predict

Sugi Predict / Compounds / SCHEMBL9162

SCHEMBL9162

SCHEMBL9162

CC(=O)Nc1ccc(B(O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.61
▸ HTT P42858 1/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ KMT2A Q03164 5/20 0.59
▸ MEN1 O00255 3/20 0.59
▸ ALDH1A1 P00352 2/20 0.59
▸ MAPT P10636 2/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ CA12 O43570 1/20 0.59
▸ BRD4 O60885 1/20 0.59
▸ NR1I2 O75469 1/20 0.59
▸ CA1 P00915 1/20 0.59
▸ CA2 P00918 1/20 0.59
▸ MB P02144 1/20 0.59
▸ CYP1A1 P04798 1/20 0.59
▸ CA3 P07451 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ RARG P13631 1/20 0.59
▸ TSHR P16473 1/20 0.59
▸ ALOX5AP P20292 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9945929 0.85 SMN1; SMN2 (0.59) SMN1; SMN2HTTL3MBTL1KMT2AMEN1
SCHEMBL861674 0.83 SMN1; SMN2 (0.84) SMN1; SMN2HTTL3MBTL1KMT2AMEN1
SCHEMBL19302408 0.82 KMT2A (0.69) SMN1; SMN2KMT2AMEN1ALDH1A1MAPT
SCHEMBL1726459 0.80 RXFP1 (0.59) SMN1; SMN2HTTL3MBTL1ALDH1A1TDP1
SCHEMBL22971706 0.79 TRPV1 (0.64) SMN1; SMN2KMT2AALDH1A1MAPTTRPV1
SCHEMBL479054 0.79 SMN1; SMN2 (0.62) SMN1; SMN2MAPTCA1CA2TRPV1
SCHEMBL15962133 0.79 SMN1; SMN2 (0.51) SMN1; SMN2HTTL3MBTL1KMT2AMEN1
SCHEMBL3789093 0.78 LMNA (0.54) SMN1; SMN2HTTL3MBTL1KMT2AMEN1
SCHEMBL1091926 0.78 PEPD (0.59) KMT2AMEN1ALDH1A1MAPTTRPV1
SCHEMBL4318569 0.78 TRPV1 (0.49) KMT2AMEN1TRPV1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 912 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119735600-A 3-Ureido substituted thieno [2,3-b ] pyridine compound and preparation method and application thereof 华东师范大学 2025-04-01 — — CN claimed
CN-118240115-A Repeatedly-processable saturated rubber and preparation method thereof 北京化工大学 2024-06-25 — — CN claimed
CN-106946920-A A kind of preparation method of 4 amino phenyl boronic acid derivative 泰力特医药（湖北）有限公司 2017-07-14 — — CN claimed
US-8361484-B2 Polymer systems for lung volume reduction therapy AERIS THERAPEUTICS, INC. (US) 2013-01-29 — — US claimed
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy CANADIAN IMPERIAL BANK OF COMMERCE (CA) 2010-02-18 — — US claimed
EP-1009451-B1 COMPOSITIONS AND THEIR USE TO PREVENT FORMATION OF ADHESIONS IN BIOLOGICAL TISSUES CALIFORNIA INST OF TECHN (US) 2003-10-29 — — EP claimed
CN-122059933-A Pyrazolo [4,3-d ] pyrimidinone derivative and preparation method and application thereof 中国科学院新疆理化技术研究所 2026-05-19 — — CN disclosed
CN-122029157-A Bilobalide derivatives for the treatment of neurological diseases and cancers 香港中文大学 2026-05-12 — — CN disclosed
US-20260124222-A1 ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
EP-4727537-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF Adaxion Therapeutics, Inc. (US) 2026-04-22 — — EP disclosed
US-20260092053-A1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2026-04-02 — — US disclosed
EP-3768675-B1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2026-04-01 — — EP disclosed
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS TORAY INDUSTRIES, INC. (JP) 2026-03-26 — — US disclosed
EP-0832082-B1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ASTRAZENECA AB (SE) 2001-11-21 — — EP disclosed
US-6258817-B1 PRODRUGS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS ZENECA LTD. (GB) 2001-07-10 — — US disclosed
WO-2001032633-A1 SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES BASILEA PHARMACEUTICA AG (CH) 2001-05-10 — — WO disclosed
US-6060475-A Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof ZENECA LIMITED (GB) 2000-05-09 — — US disclosed
US-5866568-A ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY ZENECA LIMITED (GB) 1999-02-02 — — US disclosed
EP-0832082-A1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ZENECA LIMITED (GB) 1998-04-01 — — EP disclosed
WO-1996040681-A1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ZENECA LIMITED (GB) 1996-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS AIFM2, GPX1, SOD1 SMN1; SMN2 10/4885HTT 200/4885L3MBTL1 256/4885
US-20260092053-A1 KHK INHIBITORS KHK, SLC5A2, HK1 SMN1; SMN2 1349/4885HTT 2909/4885L3MBTL1 3729/4885
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy GFER, MUC1, CTH SMN1; SMN2 3790/4885HTT 549/4885L3MBTL1 1874/4885
US-20260124222-A1 ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL6B SMN1; SMN2 3901/4885HTT 2834/4885L3MBTL1 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.